COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE) (CON-VINCE)

CON-VINCE (COvid-19 National survey for assessing VIral spread by Non-affected CarriErs) is a national, monocentric, and longitudinal study aiming to evaluate the spread dynamics of the COVID-19 disease within the Luxembourgish population. Participants who are clinically asymptomatic or present with only mild symptoms will be followed up longitudinally, regularly tested for SARS-CoV-2 by RT-PCR, antibody status, and subjected to an epidemiological, clinical and biological phenotyping to better understand the nature, dynamics of infectivity and spread of the virus in the population. CON-VINCE will also track the psychological and socio-economic impact of long-term containment measures on the general population.

Study Overview

• Status: Completed
• Conditions: COVID19

Detailed Description

To capture the dynamics and impact of the virus spread in the Luxembourgish population, data and sample collection is done every two weeks for two months (4 times in total) with a final follow-up one year after the participant's inclusion in the study. Participants complete questionnaires before each sample collection. The baseline questionnaire captures demographic data, medical history, behavioral and psychological data, and socio-economic status. Participants provided information on medical history, history of allergies, smoking, and chronic medication taken regularly. COVID-19-related data and environmental conditions of the household were obtained.

• Study Type: Observational
• Enrollment (Actual): 1870

Contacts and Locations

Study Locations

• Luxembourg
  • Strassen, Luxembourg, 1445
    • Luxembourg Institute of Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Representative panel of the Luxembourgish population

Description

Inclusion Criteria:

• Subjects aged 18 and older of both genders, with a full capacity of consent.
• SARS-CoV-2-positive individuals with an asymptomatic or oligosymptomatic infection (mild or oligosymptomatic disease course is defined as absence of fever and respiratory distress or cough not attributable to other known chronic disease).
• OR SARS-CoV-2-negative individuals at the time of inclusion.
• OR post-infectious SARS-CoV-2-negative individuals with acquired immunity to SARS-CoV-2 and a mild disease course.

Exclusion Criteria:

• Evolution of the COVID-19 disease requiring a hospital admission before inclusion in the study
• Presence of fever and respiratory distress/cough at the time of inclusion not attributable to other known chronic disease

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence and dynamics of the SARS-COV 2 infection in Luxemburg	Evaluation of the prevalence by RT-PCR and serology testing	04.2020-05.2021
Collection of samples for research	Samples will be analysed and stored for future research	04.2020-05.2021

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Psycho-social evaluation	Psychological and socio- economic impact of long-term containment measures on the general population	04.2020-05.2021

Collaborators and Investigators

• Sponsor: Luxembourg Institute of Health
• Collaborators: Centre Hospitalier du Luxembourg; Laboratoires Réunis; Luxembourg National Research Funds; University of Luxembourg/ Luxembourg Centre for Systems Biomedicine; TNS-Ilres; BioneXt Lab; Ketterthill; Laboratoire National de santé
• Investigators: Principal Investigator: Rejko Krüger, Dr, Luxembourg Institute of Health

Study record dates

Study Major Dates

• Study Start (Actual): April 10, 2020
• Primary Completion (Actual): June 10, 2021
• Study Completion (Actual): September 30, 2022

Study Registration Dates

• First Submitted: May 6, 2020
• First Submitted That Met QC Criteria: May 6, 2020
• First Posted (Actual): May 7, 2020

Study Record Updates

• Last Update Posted (Actual): February 16, 2023
• Last Update Submitted That Met QC Criteria: February 15, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: Prevalence; Coronavirus; COVID
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: CNER 202004/01; 831x6ce0d (Other Identifier: Ministry of Health); FNR/CON-VINCE (Other Grant/Funding Number: Luxembourg National Research Fund)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No